Clinical significance of Mena and Her-2 expression in breast cancer

被引:0
|
作者
Du, J. W. [1 ]
Xu, K. Y. [1 ]
Fang, L. Y. [1 ]
Qi, X. L. [1 ]
机构
[1] Anhui Univ Sci & Technol, Sch Med, Huainan City 232001, Anhui, Peoples R China
关键词
Breast cancer; Mena; Her-2; Immunohistochemistry; Clinicopathological parameter; HIGH-RISK;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to determine the expression patterns of Mena and Her-2 in breast cancer tissues and to explore their clinical significance and correlation with clinicopathological parameters. Methods: The expression of Mena and Her-2 was detected in 40 breast cancer tissues and 14 normal breast tissues by immunohistochemistry, and the relationship of Mena and Her-2 expression with clinicopathological parameters was analyzed. Results: Both Mena (70%) and Her-2 (40%) were more commonly expressed in breast cancer than in normal breast tissue (7.1%, 0%, respectively; p < 0.05); further, Mena and Her-2 expression in breast cancer were positively correlated (r = 0.530, p < 0.05). In comparing expression with clinicopathological parameters of tumor samples, Mena and Her-2 were both associated with axillary lymph node metastasis and TNM stage (p < 0.05), but not with patient age or pathological type. Conclusions: Mena and Her-2 are related to the malignancy degree and metastasis of breast cancer, and thus may play a coordinating role in the occurrence and progression of breast cancer.
引用
收藏
页码:455 / 458
页数:4
相关论文
共 50 条
  • [41] Clinical Significance of HER2-low Breast Cancer
    Zaiem, Fadi
    AbuJamea, Asem
    Kheil, Mira
    Numi, Anna
    Abbas, Omar
    Awada, Sanaa
    Almsaddi, Ragad
    Al-Juburi, Saleh
    Larson, Lauren
    Jain, Deepti
    AlSaghir, Maya
    Jang, Hyejeong
    Kim, Seongho
    Bandyopadhyay, Sudeshna
    Jaiman, Sunil
    Ali-Fehmi, Rouba
    CANCER RESEARCH, 2024, 84 (09)
  • [42] The association of miR-21, HER-2/neu, and PTEN expression and clinical outcome of breast cancer
    Lin, Hsiao-Ching
    Cheng, Ya-Wen
    Hsu, Nan-Yung
    CANCER RESEARCH, 2014, 74 (19)
  • [43] Correlation Between HER-2 Gene Amplification or Protein Expression and Clinical Pathological Features of Breast Cancer
    Shi, Pengfei
    Chen, Cheng
    Yao, Yufeng
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2019, 34 (01) : 42 - 46
  • [44] The γ-synuclein expression in breast cancer and its correlation with the expression of the HER-2/neu gene
    Kim, Seong Rae
    Choi, Won Hyuk
    Park, Jun Ho
    Nam, Eun Sook
    Cho, Seong Jin
    Park, Chan Heun
    JOURNAL OF BREAST CANCER, 2007, 10 (02) : 114 - 119
  • [45] HER-2/neu diagnostics in breast cancer
    Carney, Walter P.
    Leitzel, Kim
    Ali, Suhail
    Neumann, Rainer
    Lipton, Allan
    BREAST CANCER RESEARCH, 2007, 9 (03)
  • [46] Treatment of HER-2 positive breast cancer
    Clavarezza, Matteo
    Venturini, Marco
    EJC SUPPLEMENTS, 2008, 6 (14): : 21 - 25
  • [47] EGFR and HER-2 antagonists in breast cancer
    O'Donovan, Norma
    Browne, Brigid
    Crown, John
    Duffy, Michael J.
    Slamon, Dennis
    Clynes, Martin
    ANTICANCER RESEARCH, 2007, 27 (3A) : 1374 - 1374
  • [48] HER-2 testing in breast cancer -: Reply
    Yaziji, H
    Barry, TS
    Gown, AM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (15): : 1818 - 1818
  • [49] Immunotherapy for HER-2 positive breast cancer
    Yang, Tingting
    Kang, Lihua
    Li, Dan
    Song, Yanqiu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Clinical and Epidemiologic Significance of HER2-Low Expression in Breast Cancer in the Pathways Study
    Khoury, Thaer
    Ondracek, Rochelle Payne
    Yao, Song
    Mendocino, Lucas
    Davis, Warren
    Omilian, Angela
    Kwan, Marilyn
    Roh, Janise
    D'Addario, Lia
    Valice, Emily
    Fernandez, Daniel
    Ergas, Isaac
    Ambrosone, Christine
    Kushi, Lawrence
    CANCER RESEARCH, 2024, 84 (09)